SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Anti-OPGL [9H7] Bulk Size Ab04111-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa
Clone Number: 9H7
Alternative Name(s) of Target: CD254; Tumor necrosis factor ligand superfamily member 11; TNFSF11; TNF superfamily member 11; Osteoclast differentiation factor; ODF; Osteoprotegerin ligand; OPGL; OPTB2; Receptor activator of nuclear factor kappa-B ligand; RANKL; hRANKL2; TNF-related activation-induced cytokine; TRANCE; sOdf; TNLG6B
UniProt Accession Number of Target Protein: O14788
Published Application(s): in vivo, NTRL, SPR, ELISA
Published Species Reactivity: Human, Cynomolgus Monkey
Immunogen: The original antibody was generated by immunizing transgenic HuMab mice with purified recombinant OPGL derived from *E. coli* or CHO cells. Sera from immunized mice were tested for antibody binding to OPGL.
Specificity: This antibody is specific for human OPGL. *In vivo* experiments have shown cross reactivity with Cynomolgus Monkey OPGL.
Application Notes: The binding affinity of this antibody's original format (human IgG1) to hOPGL was confirmed by ELISA. Its binding kinetics to hOPGL 140 and hOPGL 158 was measured by SPR analysis; a K_D of 0.193 nM was measured for hOPGL 140. This antibody was evaluated for its neutralizing activity against osteoclast formation induced by Osteoprotegerin ligand (OPGL) using RAW 264.7 cells, as measured by tartrate-resistant acid phosphatase (TRAP) activity; it inhibited osteoclast formation in a dose-dependent manner with an IC_{50} of 129 ng/ml. This antibody's pharmacokinetics and *in vivo* activity were assessed in cynomolgus monkeys. The antibody's levels in the serum declined slowly over the testing period; the last detectable measurement on day 49 showed a serum concentration of ~100 ng/ml. serum N-telopeptide (serum N-Tx) levels were greatly reduced compared to baseline immediately following injection (~minus 45%), further decreased to ~minus 75% over four days, and remained stable for a period of two weeks, after which they began to gradually increase until no longer lower than baseline in a statistically significant

manner between day 35 to 42 (US7718776B2).
Antibody First Published in: PMID:
Note on publication:

Product Form

Size: 1 mg Purified antibody in bulk size.
Purification: Protein A affinity purified
Supplied In: PBS only.
Storage Recommendation: Store at 4ºC for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20ºC.
Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.